CLDX Celldex Therapeutics

Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call

Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call

HAMPTON, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2018 financial results and to provide an update on key research and development and business objectives for the remainder of 2018.

The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at . The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 4768019.

A replay of the call will be available approximately two hours after the live call concludes through August 15, 2018. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 4768019. The webcast will also be archived on the Company's website.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

Celldex Therapeutics, Inc.

(781) 433-3161

EN
02/08/2018

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolv...

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temper...

April 17, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics to Participate in the Leerink Partners Global Bio...

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET. A webcast of the presentation will be available on the  page of the section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading...

March 8, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ...

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the . A replay of the webcast will be available for at le...

March 5, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics Announces Closing of Public Offering of Common St...

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold ...

March 5, 2024 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public ...

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stoc...

March 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch